Caribou Biosciences, Inc. (CRBU)
| Market Cap | 58.36M -76.2% |
| Revenue (ttm) | 10.04M +10.0% |
| Net Income | -103.40M |
| EPS | -1.08 |
| Shares Out | 107.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,260,902 |
| Open | 0.5199 |
| Previous Close | 0.5190 |
| Day's Range | 0.5116 - 0.5500 |
| 52-Week Range | 0.4425 - 3.5350 |
| Beta | 2.31 |
| Analysts | Buy |
| Price Target | 5.75 (+956.21%) |
| Est. Earnings | Nov 11, 2026 |
About CRBU
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM... [Read more]
Financial Performance
In 2025, Caribou Biosciences's revenue was $11.16 million, an increase of 11.66% compared to the previous year's $9.99 million. Losses were -$148.13 million, -0.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRBU stock is "Buy." The 12-month stock price target is $5.75, which is an increase of 956.21% from the latest price.
News
Caribou Biosciences moved to No Rating at BofA
BofA moved to No Rating on Caribou Biosciences (CRBU) after the company announced a strategic review and plans to discontinue development of vispa-cel and CB-011. The planned discontinuation of both…
Caribou Biosciences downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Caribou Biosciences (CRBU) to Neutral from Buy without a price target The company is exploring strategic alternatives as all of its clinical programs are halted, the analyst...
Why is Caribou Biosciences Stock (CRBU) Down 43% Today?
Shares in Caribou Biosciences ($CRBU) plunged over 43% today as investors reacted to the company’s decision to potentially put itself up for sale and slash jobs because of a lack…
Caribou Biosciences downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Caribou Biosciences (CRBU) to Market Perform from Outperform with a price target of $1, down from $4. The firm cites decreased visibility into Caribou’s outlook as an ongoing…
Caribou Biosciences downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Luca Issi downgraded Caribou Biosciences (CRBU) to Sector Perform from Outperform with a price target of $1, down from $10. The company is exploring strategic alternatives and…
Caribou Biosciences downgraded to Hold from Buy at Brookline
Brookline downgraded Caribou Biosciences (CRBU) to Hold from Buy after the company said it is evaluating strategic alternatives.
Caribou Biosciences trading resumes
16:25 EDT Caribou Biosciences (CRBU) trading resumes
Caribou to discontinue development activities, explore alternatives
Caribou Biosciences (CRBU) announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell...
Caribou Biosciences trading halted, news pending
16:01 EDT Caribou Biosciences (CRBU) trading halted, news pending
Caribou Biosciences to Evaluate Strategic Alternatives
-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --
Caribou Biosciences reports Q2 EPS (24c), consensus (31c)
Reports Q2 revenue $1.5M, consensus $2.25M. “At Caribou, we are redefining what patients and physicians should expect from allogeneic CAR-T cell therapy,” said Rachel Haurwitz, president and CEO of Ca...
Caribou Biosciences price target lowered to $5 from $6 at BofA
BofA lowered the firm’s price target on Caribou Biosciences (CRBU) to $5 from $6 and keeps a Buy rating on the shares. The firm adjusted targets for several names in…
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overc...
Caribou Biosciences Quarterly report: Q2 2026
Caribou Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Caribou Biosciences Earnings release: Q2 2026
Caribou Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Caribou Biosciences Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
The discussion highlighted pivotal-ready vispa-cel and promising CB-011 data, both leveraging a highly specific genome editing platform to address access and efficacy gaps in hematologic malignancies. Vispa-cel offers rapid, off-the-shelf delivery and strong safety, while CB-011 shows durable responses in late-line myeloma.
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...
Caribou Biosciences Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and a proposed officer exculpation amendment, which was not approved. All other proposals passed, and no questions were raised by stockholders. Voting results will be reported to the SEC.
Caribou Biosciences presents ANTLER trial results at EHA
Caribou Biosciences (CRBU) announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase 1 clinical trial ...
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient admi...
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case st...
Caribou Biosciences Slides: Corporate presentation
Caribou Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
Caribou Biosciences Proxy statement: Proxy filing
Caribou Biosciences filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Two off-the-shelf CAR T programs are advancing: vispa-cel (pivotal-ready for lymphoma) and CB-011 (phase I for myeloma). The pivotal ANTLER III study targets patients lacking access to autologous CAR T, with rapid timelines and global reach. Key data updates are expected at EHA and by year-end.
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...